Merck KGaA has dosed the first patient in its Phase III clinical programme, evaluating enpatoran in individuals with lupus who have active skin manifestations.
Newleos Therapeutics has dosed the first participant in its Phase Ib clinical study evaluating NTX-2001, a partial agonist of TAAR1, for AUD.
Pfizer is hoping for earlier use of Elrexfio (elranatamab) in relapsed or refractory multiple myeloma (RRMM) after the drug showed benefit as a second-line therapy in a Phase III ...
An independent international safety monitoring board has given the ENIGMA-TRS 1 trial the go-ahead to continue as planned in schizophrenia.
The JCA aims to centralise clinical assessment across the EU but tight timelines and stringent evidence requitements have cast doubt over the how fit for purpose the process is. Photo by Mahir Asadli ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results